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https://doi.org/10.1016/j.stemcr.2019.11.009SUMMARYDifferentiation of human embryonic stem cells into pancreatic b cells holds great promise for the treatment of diabetes. Recent advances
have led to the production of glucose-responsive insulin-secreting cells in vitro, but resulting cells remain less mature than their adult
primary b cell counterparts. The barrier(s) to in vitro b cell maturation are unclear. Here, we evaluated a potential role for microRNAs.
MicroRNA profiling showed high expression of let-7 family microRNAs in vivo, but not in in vitro differentiated b cells. Reduced levels
of let-7 in vitrowere associated with increased levels of the RNA binding protein LIN28B, a negative regulator of let-7 biogenesis. Ablation
of LIN28B during human embryonic stem cell (hESC) differentiation toward b cells led to amoremature glucose-stimulated insulin secre-
tionprofile and the suppression of juvenile-specific genes. However, let-7 overexpressionhad little effect. These results uncover LIN28B as
a modulator of b cell maturation in vitro.INTRODUCTION
A growing number of people are suffering from diabetes
worldwide (Roglic and World Health Organization, 2016).
Diabetes is a disease of imbalance between blood insulin
and glucose levels secondary to pancreatic islet b cell loss
or impaired function (Cerf, 2013). At present, type 1 dia-
betic (T1D) and end-stage type 2 diabetic (T2D) patients
rely on exogenous injection of insulin to control blood
glucose. While life sustaining, this therapy is arduous and
prone to complications as it is virtually impossible to
mimic the dynamic changes in insulin production and
secretion performed by endogenous b cells. Transplanta-
tion of cadaveric islet cells provides an alternative option
resulting in effective glycemic control, but these cells are
in limited supplymaking it unfeasible for broad implemen-
tation (Sneddon et al., 2018). b cells produced by the differ-
entiation of pluripotent stem cells, both human embryonic
stem cells (hESCs) and induced pluripotent stem cells
(iPSCs) hold great promise in filling this gap. Recent ad-
vancements have greatly improved the production of these
cells in vitro (Nair et al., 2019; Velazco-Cruz et al., 2019;
Veres et al., 2019). However, there remain differences be-
tween in vitro produced cells and endogenous adult b cells
in their gene expression profile and secretory capacity.
Therefore, it is important both conceptually and practically
to understand the barriers to in vitro differentiation towardStem
This is an open access artimature adult b cells. Since euglycemia can be restored in
diabetic mice by transplantation of stem cell-derived
pancreatic progenitors or b cell populations, it is speculated
that the in vivo environment supports further maturation
of generated b cells, although the changes that occur in b
cells upon transplantation have not been elucidated.
Much of the progress in b cell differentiation has been
achieved by optimizing combinations of signaling peptides
and chemicals that recapitulate events that occur during
normal development in vivo (Liew, 2010; Nair and Hebrok,
2015). MicroRNAs (miRNAs) represent another type of
small molecule. They exist endogenously, function by
coordinating the regulation of many targets, and can
have profound effects on developmental cell fate decisions
(Friedman et al., 2009; Shenoy and Blelloch, 2014). The
let-7 family comprises one of the evolutionarily most
conserved families of miRNAs (Friedman et al., 2009).
Let-7 exists in a negative feedback loop with the RNA bind-
ing proteins LIN28A and LIN28B (Shyh-Chang and Daley,
2013). Let-7 inhibits production of the LIN28 proteins,
while the LIN28 proteins suppress biogenesis of Let-7.
This loop forms a bistable regulatory switch in a number
of cell fate decisions (Thornton and Gregory, 2012). Of
note, both let-7 and LIN28 have many other targets. Let-
7 miRNAs act through their many targets to generally pro-
mote differentiation and suppress growth (Kumar et al.,
2008; Roush and Slack, 2008), whereas LIN28 has theCell Reports j Vol. 14 j 9–20 j January 14, 2019 j ª 2019 The Authors. 9
cle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
opposite effect both by inhibiting let-7 and through let-7
independent mechanisms, such as increasing translation
of cell-cycle mRNAs (Tsialikas and Romer-Seibert, 2015).
Here, we report an increase in let-7 and decrease in
LIN28B during b cell maturation. The manipulation of
LIN28B, but not let-7 levels, promoted a switch to a more
mature adult-like b cell phenotype in vitro, uncovering a
let-7 independent role for LIN28B in inhibiting b cell
maturation.RESULTS
Let-7 Expression Increases with b Cell Maturation
To determine a potential role formiRNAs in thematuration
of pancreatic b cells, we performed small RNA sequencing
(RNA-seq) of in vitro stem cell-derived, in vivo matured,
and human cadaveric islet cells. Human in vitro derived
b-like cells were produced from hESCs using an INS-GFP re-
porter hESC line (Micallef et al., 2012), where GFP expres-
sion is under the control of the endogenous insulin
promoter (Figure 1A, hESC immature b-like cells) (Faleo
et al., 2017; Russ et al., 2015). Typically, 39.26% ± 4.09%
INS-GFP+ cells were generated (Figures S1A and S1B). The
b-like cells were also transplanted under the kidney capsule
of immunodeficient mice to allow for further in vivomatu-
ration for 4–5 weeks (referred to as in vivomatured hESC b
cells). As the differentiation protocol produces a heteroge-
neous mixture of cells, the insulin-producing cells in
both in vitro derived cultures and in vivo matured grafts
were isolated by their GFP expression using fluorescence-
activated cell sorting before transcriptome analysis. Cadav-
eric human islets were used as a proxy for pancreas-derived
human b cells, although these islets contain a mix of cell
types (approximately 50% b cells) (Cabrera et al., 2006).
Analysis of small RNA-seq data for human islet cells
versus in vitro derived hESC b-like cells uncovered 554
significantly differentially expressed miRNAs (adjusted p
value < 0.05) (Figure 1B; Table S1). Of note, this contained
a large number of let-7 family members that were highly
upregulated in the islet cells relative to the in vitro derived
cells (Figure 1B, red dots). The increase in let-7 could have
been contributed by non-b cells within the cadaveric hu-
man islets. Therefore, we next analyzed small RNA-seq
data from in vivo matured INS-GFP+ hESC b cells versus
INS-GFP+ hESC b-like cells (Figures 1C; Table S2). This com-
parison of isogenic purified INS-GFP+ cell populations con-
trols for genetic variation and cellular heterogeneity. Still,
similar to the human islets, the in vivo matured b cells
showed elevated expression of multiple let-7 family mem-
bers relative to the b-like cells (Figure 1C, red dots).
Next, we validated the association between let-7 expres-
sion and b cell maturation using a differentiation protocol10 Stem Cell Reports j Vol. 14 j 9–20 j January 14, 2019that allows for further maturation of b-like cells in vitro, by
reaggregation and culture of purified insulin-expressing
cells as organoids (Nair et al., 2019). We call the resulting
in vitro matured cells as hESC-enriched b cell clusters
(eBCs) (Figure 1A). We performed qRT-PCR for representa-
tive let-7 family members in hESC b-like cells, in vitro
matured hESC eBCs, in vivomatured hESC b cells, and hu-
man islets (Figure 1D). Consistent with the sequencing
data, both human islet cells and in vivo matured hESC b
cells showed dramatically increased levels of all the let-7
family members. hESC eBCs also showed elevated levels
of let-7 relative to hESC b-like cells, but the levels were
below human islets and in vivo matured hESC b cells (Fig-
ure 1D). Together, these data show a positive association
between let-7 levels and the maturation of b cells.
LIN28B Expression Is Downregulated during b Cell
Maturation
Let-7 expression is regulated both transcriptionally and
post-transcriptionally (Roush and Slack, 2008). Post-tran-
scriptionally, the RNA binding proteins LIN28A&B sup-
press the biogenesis of mature let-7 family members
(Nam et al., 2011; Piskounova et al., 2011; Viswanathan
et al., 2008). In turn, let-7 itself functions to suppress hun-
dreds of downstream mRNA targets including LIN28A&B
(Rybak et al., 2008; Yang et al., 2010). To evaluate the
impact of b cell maturation on the let-7 regulatory network
of genes, we performed mRNA-seq in hESC b-like cells,
in vivomatured hESC b cells, and human islet cells. Differ-
ential expression between human islets and hESC b-like
cells showed differential expression of many transcripts
(Figure 2A, blue dots, adj p < 0.05, Table S3), including
elevated levels of LIN28B (but not LIN28A) in the in vitro
cells (LIN28B, green dot, adj p = 4 3 105). Surprisingly,
however, analysis of high-scoring Targetscan predicted
targets of let-7 showed roughly equal distribution between
up- and downregulated genes (Figure 2B, red dots). Further-
more, cumulative density analysis on the fold change of
let-7 targets versus all genes, showed no shift in the curve
(Figure 2C). We hypothesized this may be due to a con-
founding effect due to presence of other islet cell types be-
sides b cells in human islets. Therefore, we next compared
the GFP-sorted populations from hESC b-like cells and
in vivo matured hESC b cells (Figure 2D, Table S4). Fewer
genes were differentially expressed between these cell
types, consistent with the common origin, and hence
reduced heterogeneity between the two cell populations
(Figure 2D, blue dots, adj p < 0.05). Again, LIN28B (but
not LIN28A) was up in hESC b-like cells (LIN28B, green
dot, adj p = 0.044). Also, predicted targets of let-7 were
distributed equally among up- and downregulated genes
(Figure 2E, red dots) and were not shifted in the cumulative
density plot (Figure 2F). We validated the LIN28B findings
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Figure 1. Let-7 Is Upregulated at Late-Stage b Cell Maturation
(A) Schematic outlining the differentiation protocol employed. In vivo matured b cells: b cells isolated from grafts post transplant. eBCs,
enriched b clusters generated after inducing further maturation in vitro. Adapted from Nair et al. (2019).
(B) Volcano plot of differentially expressed miRNAs in hESC b-like cells (n = 3, independent samples) and human islets (n = 3, independent
samples). Significant hits are shown in blue (p < 0.05). let-7 family hits are shown in red.
(C) Volcano plot of differentially expressed miRNAs in hESC b-like cells (n = 3, independent samples) and in vivo matured b cells (n = 3,
independent samples). Significant hits are shown in blue (p < 0.05). let-7 family hits are shown in red.
(D) qRT-PCR verification of representative let-7 family member expression in human islets (n = 3, independent samples), hESC b-like cells
(n = 4, independent samples), hESC eBCs (n = 3, independent samples), and in vivomatured b cells (n = 2, independent samples). Values are
average ± SEM. Statistical significance was calculated using unpaired two-tailed t test. *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not
significant.
See also Figure S1 and Tables S1 and S2.by qRT-PCR and extended them to the hESC eBCs (Fig-
ure 2G). There was a progressive reduction in LIN28 levels
when starting with hESC b-like cells, followed by hESC
eBCs, in vivomatured hESC b cells, and finally human islet
cells. The negative correlation between let-7 levels and
LIN28B levels is consistent with their known negative feed-
back on each other (Rybak et al., 2008; Thornton andGreg-
ory, 2012). However, the lack of enrichment of let-7 targets
among the upregulated genes in hESC b-like cells suggeststhat let-7 downstream function may not play a major role
in b cell maturation.
LIN28B Downregulation Promotes hESC b Cell
Maturation
As LIN28B was up and let-7 was down in the in vitro derived
cells (both b-like cells and eBCs) relative to in vivomatured
hESC b cells and human islet cells, we asked if suppression
of LIN28B could promote further maturation of b cells. ToStem Cell Reports j Vol. 14 j 9–20 j January 14, 2019 11
Figure 2. LIN28 Is Downregulated at Late-Stage b Cell Maturation
(A) Volcano plot of differentially expressed mRNAs in hESC b-like cells (n = 3, independent samples) and human islets (n = 3, independent
samples). Significant hits are shown in blue (p < 0.05). LIN28A and LIN28B are highlighted in yellow and green, respectively.
(B) Same as (A), except let-7 family target genes (predicted by TargetScan) are highlighted in red.
(C) Cumulative distribution of differential expression of all expressed mRNAs and let-7 targets, predicted by TargetScan, in the human
islets versus hESC b-like cells from (A).
(D) Volcano plot of differentially expressed mRNAs in hESC b-like cells (n = 3, independent samples) and in vivo matured b cells (n = 3,
independent samples). Significant hits are shown in blue (p < 0.05). LIN28A and LIN28B are highlighted in yellow and green, respectively.
(legend continued on next page)
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suppress LIN28B, we initially attempted knocking down
LIN28 using a virally transduced shRNA against the
Lin28b mRNA. However, transduction even of a control
vector led to poor differentiation (data not shown). There-
fore, we implemented a doxycycline-inducible CRISPR
knockout strategy with guide RNAs on either side of exon
3 (iCrLIN28B) (Gonzalez et al., 2014) (Figure 3A, also see
Experimental Procedures). Both gRNAs are constitutively
expressed under the control of U6 promoters, while Cas9
protein expression depends on doxycycline exposure.
Doxycycline was introduced at different times during the
differentiation process and the cells were treated until the
end of the differentiation protocol (Figure S2A). Addition
of doxycycline at day 0 resulted in 100% indel formation,
but caused poor differentiation of INS-GFP+ cells (Figures
S2B and S2C). In contrast, addition at day 3 resulted in
78% indel formation with only a marginal decrease in the
number of INS-GFP+ cells at day 20 of differentiation (Fig-
ure S2D). Addition of doxycycline at later time points
including days 6, 8, 10, and 14 resulted in lower levels of in-
del formation (Figure S2B), indicating a relative resistance
to the inducible CRISPR knockout at later stages of differen-
tiation. Furthermore, cells assessed at the b-like and eBC
stages thatwere treatedwith doxycyline fromday 3, consis-
tently showed 70%–80% indel formation (Figure S2E). This
result was corroborated with western blot analysis showing
a 50% reduction in LIN28B protein levels at b-like stage of
differentiation (Figure 3B). Because addition of doxycy-
cline starting at day 3 resulted in the greatest loss of
LIN28B while retaining near normal INS-GFP+ cell
numbers, further experiments were performed using this
treatment regime.
In particular, we evaluated the effect of iCrLIN28B on
let-7 production and b cell maturation on hESC eBCs.
iCrLIN28B led to a small, albeit significant, increase in
let-7 levels as determined by qRT-PCR for four representa-
tive let-7 family members (Figure 3C). To determine the
impact of LIN28B depletion on b cell maturation, we first
analyzed the expression of key b cell markers. qRT-PCR
showed enhanced expression of a number of markers of
b cells including PDX1, NKX6.1, NKX2.2, MAFA, NEU-
ROD1, and ISL1 (Figure 3D). PDX1, NKX6.1, NKX2.2,
and NEUROD1 are important in the maintenance of b
cell identity and function (Chao et al., 2007; Gao et al.,
2014; Gu et al., 2010; Schaffer et al., 2013). MAFA regulates
insulin expression and promotes the functional matura-(E) Same as (D), except let-7 family target genes (predicted by Targe
(F) Cumulative distribution of differential expression of all expressed
matured b cells versus hESC b-like cells from (D).
(G) qRT-PCR verification of LIN28B expression in human islets (n =
samples), hESC eBCs (n = 3, independent samples), and in vivo matur
Statistical significance was calculated using unpaired two-tailed t tetion of b cells (Artner et al., 2010; Hang and Stein, 2011).
ISL1 maintains the terminal differentiation program of b
cells (Ediger et al., 2017).We also conducted a protein level
characterization of these b cell markers by flow cytometry
(Figure S3). Percentage of cells expressing PDX1, NKX6.1,
PAX6, and ISL1 trended higher in LIN28B-deleted cells
than controls, although the statistical tests did not reach
a p value of 0.05.
Next, we tested the impact of LIN28 depletion on b cell
function using both static and dynamic glucose stimula-
tion insulin secretion (GSIS) studies. In the static GSIS
assay, the fold increase in insulin release into the media
was measured following an increase in the glucose concen-
tration from 2.8 to 16.7 mM (stimulation index). The assay
showed a significant, roughly 2-fold greater increase in the
stimulation index in the doxycycline-treated versus un-
treated iCrLIN28B eBCs (Figure 3E; Table S5). For the dy-
namic assay, iCrLIN28B doxycycline-treated or untreated
eBCs were perfused with low- and high-glucose buffers
and insulin release was measured over time. In contrast
to the static assay, the dynamic perifusion assay provides
a comprehensive view of b cell function including the
basal, first, and second phases of insulin secretion. The
perifusion assay showed higher levels of insulin secretion
in both the low- and high-glucose treatments for the doxy-
cycline-treated iCrLIN28B eBCs relative to their untreated
counterparts (Figure 3F). These perifusion results are highly
reminiscent of differences in the secretion profiles previ-
ously reported for adult versus juvenile primary human
islet samples (Arda et al., 2016).
The Arda et al. study also measured gene expression dif-
ferences in adult versus juvenile primary human islet sam-
ples by RNA-seq.We therefore performed a similar RNA-seq
comparison between our doxycycline-treated and un-
treated iCrLIN28B hESC eBCs (Figure S4A; Table S6). To
compare the gene expression changes in our experiments
with theirs we performed gene set enrichment analysis
(GSEA) for genes upregulated in either adult or juvenile pri-
mary human islets. Although there was no enrichment for
adult upregulated genes in our doxycycline-treated sam-
ples there was a highly significant depletion of the juvenile
upregulated genes (Figures 3G and S4B). Together, these
data show that the reduction of LIN28B during differentia-
tion of hESCs to b cells in vitro promotes their maturation
with a switch from a more juvenile to a more adult-like
primary human b cell phenotype.tScan) are highlighted in red.
mRNAs and let-7 targets, predicted by TargetScan, in the in vivo
3, independent samples), hESC b-like cells (n = 4, independent
ed b cells (n = 3, independent samples). Values are average ± SEM.
st. *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant.
Stem Cell Reports j Vol. 14 j 9–20 j January 14, 2019 13
***
D F
G
C
B
A
0 20 40
50
70
90
110
130
150
170
Time (min)
C
-p
ep
ti
d
e(
p
g
/m
in
/1
00
cl
u
st
er
s)
20mM Glu
2.8mM
E
iCr
LIN
28B
Do
x-
iCr
LIN
28B
Do
x+
0
1
2
3
4
5
6
7
8
S
tim
ul
at
io
n
In
de
x
PD
X1
So
x9
PA
X6
NE
UR
OD
1
MA
FA
NK
X2
.2
NK
X6
.1
ISL
1
0
2
4
6
8
R
el
at
iv
e
m
R
N
A
ex
pr
es
si
on *
p=0.05
iCrLIN28B Dox-
iCrLIN28B Dox+
let-
7a
let-
7b
let-
7d
let-
7g
let-
7f
let-
7c
0.0
0.5
1.0
1.5
2.0
R
el
at
iv
e
m
iR
N
A
ex
pr
es
si
on
*
*
**p=0.06
LIN28B iso 1
LIN28B iso 2
GAPDH
LIN
28B
iso
1
LIN
28B
iso
2
0.0
0.5
1.0
1.5
R
el
at
iv
e
pr
ot
ei
n
ex
pr
es
si
on iCrLIN28B Dox-
iCrLIN28B Dox+
DOX- DOX+
iCrLIN28B Dox-
iCrLIN28B Dox+
EXON 3 EXON 4
LIN28B
3’-GGATTTAGAAGCCTAAAAGA-5’ gRNA1
gRNA2 5’-CTACAGAAAAGAAAACCAAAGGG-3’
U6SA 2A Puro
SA 2A Neo CAG M2rtTA
hAAVS1 TALENs
1
hAAVS1 locus
2
2
3
3
1
U6 gRNA1Cas9 gRNA2TRE
-0.3
-0.1
-0.5
0.0
Juvenile Gene Set
p=0.000
FDR=0.000
-0.2
-0.4
Up in iCrLIN28B dox+ Up in iCrLIN28B dox-
E
nr
ic
hm
en
tS
co
re
(E
S
)
iCrLIN28B dox-
iCrLIN28B dox+
60 80
2.8mM
AUC
0
1000
2000
3000
4000
5000 p= 0.06
***
*
*
*
*
*
Figure 3. LIN28B Downregulation Promotes hESC-b Cell Maturation
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Let-7UpregulationAlone Is Insufficient toDrive hESC-
b Cell Maturation
Next we asked whether let-7 is acting downstream of
LIN28B depletion. Induction of iCrLIN28 led to a small in-
crease in let-7 levels (Figure 3C). Analysis of the differential
expression between uninduced and induced iCrLIN28
showed no enrichment of let-7 targets among the downre-
gulated set of genes (Figures S4C and S4D). To directly test
the impact of let-7 on b cell maturation, we generated a cell
line where a doxycycline-inducible let-7a/f/b transgene
was targeted to the hAAVS1 locus (iLET-7) (Figure 4A).
Doxycycline was added from day 14 to day 27 to induce
let-7 at the later stages of differentiation (Figure 4B). Doxy-
cycline treatment did not affect the percent of INS-GFP+
cells measured at day 20 (Figure S4E). qRT-PCR showed a
2- to 6-fold increase in let-7 in doxycycline-treated cells
relative to no doxycycline controls, significantly higher
than seen in the iCrLIN28B cells (Figure 4C, compare
with 3C). These levels did not reduce LIN28B expression,
but did suppress another well-known let-7 target, HMGA2
(Figure 4D). Static GSIS assays on the resulting day 27
eBCs did not show an improvement in the let-7-induced
cells relative to uninduced controls, unlike Lin28B-deleted
cells (Figure 4E, compare with Figures 3E; Table S5). Tran-
scriptional markers of maturation were also mostly un-
changed (Figure 4F). These data suggest that, while LIN28
acts a barrier to b cellmaturation, it is likely acting indepen-
dent of its role as an inhibitor of let-7 biogenesis.DISCUSSION
Our findings uncover an important function for LIN28B
during the course of hESC b cell maturation. The levels of(B) Western blot analysis of LIN28B in d20 (hESC b-like) clusters ge
cycline during differentiation. Dox–, no doxycycline treatment. Dox+
western blot. Right panel: quantification of four independent western
GAPDH). Values are average ± SEM. Statistical significance was calcu
0.001; n.s., not significant.
(C) qRT-PCR analysis of representative let-7 family members in iCrLI
dependent samples for Dox–, n = 7 independent samples for Dox+. Val
unpaired two-tailed t test. *p < 0.05, **p < 0.01, ***p < 0.001; n.s.
(D) qRT-PCR analysis of selected gene expression in hESC eBCs plus/mi
in (C).
(E) Static glucose-stimulated insulin secretion (GSIS) of iCrLIN28B eB
Dox–, n = 22 independent samples, for Dox+. Values are average ± SE
t test. *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant.
(F) Dynamic GSIS of iCrLIN28B hESC eBCs in perifusion assays. Dox tr
dependent samples for Dox+. Values are average ± SEM. Area under t
represent the standard error. Statistical significance was calculated u
(G) GSEA of differentially expressed genes between Dox+ versus Dox–
regulated in juvenile versus adult primary human b cells (Arda et al.,
See also Figures S2, S3, and S4 and Tables S5 and S6.let-7 and LIN28B correlate with the maturation status of
the b cells. Let-7 family miRNAs were upregulated, while
LIN28B was downregulated as the cells matured; human is-
lets contain the highest levels of let-7 and lowest levels of
LIN28B, followed by in vivo matured transplanted b cells,
in vitromatured eBCs, and finally b-like cells. Furthermore,
using an inducible CRISPR-Cas9 system we found that the
deletion of LIN28B during the course of differentiation
to eBCs improved GSIS. Interestingly, the change in the
GSIS profile is reminiscent of the change previously re-
ported when comparing adult versus juvenile primary
human islets (Arda et al., 2016). Also consistent with this
previous report is the observation that inducible deletion
of LIN28B led to the downregulation of genes characteristic
of juvenile primary human islets. In addition, the expres-
sion of a number of markers of pancreatic b cell function
and maturation, including PDX1, NKX6.1, MAFA, PAX6,
and ISL1, were higher upon LIN28B deletion. Together,
these findings show that LIN28B suppresses maturation
of hESC-derived b cells.
How LIN28B suppresses maturation is unclear. A major
role of LIN28B is to inhibit the biogenesis of let-7 (Piskou-
nova et al., 2011). However, in the context of hESC differ-
entiation toward b cells, the reduction of LIN28B led to a
very modest increase in the levels of let-7 family members.
Furthermore, there was no enrichment among downregu-
lated genes for let-7 targets and the overexpression of let-
7 to levels higher than seen in LIN28B-deleted cells did
not promote maturation. Therefore, LIN28 appears to be
acting through let-7-independent mechanisms to enhance
b cell maturation. Let-7-independent roles for LIN28 have
been previously reported in different contexts (Peng
et al., 2011; Tsialikas and Romer-Seibert, 2015; Xu et al.,
2009; Zhang et al., 2016; Zhu et al., 2011). Importantly,nerated from iCrLIN28B line plus/minus Cas9 induction with doxy-
, doxycycline treatment from d3 to d20. Left panel: representative
blots (n = 4, independent samples, two LIN28 isoforms relative to
lated using paired two-tailed t test. *p < 0.05, **p < 0.01, ***p <
N28B hESC eBCs plus/minus induction of Cas9 as in (B). n = 5 in-
ues are average ± SEM. Statistical significance was calculated using
, not significant.
nus induction of Cas9 as in (B). Number of samples and statistics as
Cs. Doxycycline treatment as in (B). n = 17 independent samples for
M. Statistical significance was calculated using unpaired two-tailed
eatments as in (B). n = 4 independent samples for Dox–, n = 4 in-
he curve (AUC) was calculated for the secretion profiles. Error bars
sing unpaired two-tailed t test.
iCrLIN28B hESC eBCs on previously identified gene set found up-
2016).
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Figure 4. Let-7 Upregulation Alone Is Insufficient to Drive hESC-b Cell Maturation
(A) Generation of iLET-7 cell line. Pre-let-7a/f (m) and pre-let-7b (m) are genomic sequences for let-7a/f and let-7b precursors with LIN28
binding region mutated (see Experimental Procedures). OE, overexpression.
(B) Schematic outlining let-7 induction protocol. Doxycycline treatment was from d14 to d27. Fluorescence-activated cell sorting was
performed on d20. GSIS and qRT-PCR were performed on d27.
(legend continued on next page)
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our results do not rule out a role for the very high levels of
let-7 seen in in vivomatured b cells and adult primary islets
promote b cell maturation. We were not able to achieve
those levels in our experiments.
A connection between LIN28 and glucose metabolism
has been reported in mice. Whole-body LIN28A- and
LIN28B-overexpressing transgenic animals are more sen-
sitive to insulin and have reduced peripheral glucose
levels (Zhu et al., 2011). These results compared with
ours suggest opposite effects of LIN28 in the cells that pro-
duce insulin versus cells that receive the insulin signal.
However, caution should be taken when comparing
mouse and human b cell maturation. For example, in
mouse, increased basal insulin secretion has been associ-
ated with immaturity (Blum et al., 2012; Puri et al.,
2018), while in human, both basal and stimulated insulin
secretion is higher in adult versus juvenile b cells
(Arda et al., 2016).
Poor glucose management is associated with long-term
diabetic consequences including diabetic retinopathy, ne-
phropathy, and neuropathy (Cade, 2008). Transplantation
of hESC-derived b cells holds great promise for improving
glucose management and thus minimizing the negative
consequences. Understanding barriers to b cell maturation
has the potential to improve the functionality of trans-
planted cells. Our work provides insight into one such bar-
rier whose activity could be targeted by ongoing efforts to
find small-molecule inhibitors of LIN28 and its partners
(Roos et al., 2016).EXPERIMENTAL PROCEDURES
Cell Culture and hESC-b Cell Differentiation
Undifferentiated INS-GFP hES cells (Micallef et al., 2012) were
maintained and differentiated into hESC-b like cells and eBCs
as described previously (Nair et al., 2019; Russ et al., 2015). Hu-
man islets were from the UCSF Islets and Cellular Production Fa-
cility. The procurement and use of human islets used in the
study was approved by the institutional biosafety committee
at UCSF. The study is compliant with all relevant ethical regula-
tions regarding research involving human participants, and
informed consent was obtained by all participants at the isola-
tion facility.(C) qRT-PCR analysis of representative let-7 family members in iLET-
samples for Dox–, n = 5 independent samples for Dox+. Values are av
two-tailed t test. *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not sign
(D) qRT-PCR analysis of LIN28B and HMGA2 expression in iLET-7 hESC e
(C).
(E) Static GSIS of iLET-7. Doxycycline treatment as in (B). n = 11 ind
Values are average ± SEM. Statistical significance was calculated usi
iCrLIN28B in Figure S4E.
(F) qRT-PCR analysis of selected gene expression in iLET-7 hESC eBCs
See also Figure S4.Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (NSG) were obtained
from Jackson Laboratories. Mice used in this study were main-
tained according to protocols approved by the University of
California, San Francisco Committee on Laboratory Animal
Resource Center. Mouse kidney capsule grafts have been described
previously (Russ et al., 2015).
Flow Cytometry
Stained cells were run on LSRFortessa X20 DualData and analyzed
with FlowJo software. Detailed staining methods including anti-
bodies in Supplemental Information.
iCRISPR LIN28 and iLet7
Construction of the iCRISPR line was built as described previously
(Gonzalez et al., 2014). The iLET-7 strategy is shown in Figure 4A.
Details in Supplemental Information.
Small RNA-Seq and RNA-Seq
Small RNA-seq libraries were made as described previously
(Hafner et al., 2012). RNA-seq libraries were made by using
SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing (Takara)
and Nextera XT DNA Library Preparation kit (Illumina)
thereafter.
Small RNA-Seq and RNA-Seq Data Analysis
For RNA-seq analysis, the data were preprocessed using Kallisto
(Bray et al., 2016) and index to Gencode v.24. For the miRNA-seq
analysis, reads were aligned using Bowtie v1.1.2 (-n 0 -L 18 -best)
to a hairpin genome downloaded from miRbase (Langmead
et al., 2009). Differential expression analysis was performed using
in R using the Limma-Voom analysis (Liu et al., 2015; Ritchie et al.,
2015). Let-7 targets were obtained from the TargetScan Release
7.1:June 2016 let-7-5p/98-5p list. GSEA analysis was performed
using the current release (July 16, 2018) from http://www.
gsea-msigdb.org/gsea/index.jsp (Mootha et al., 2003; Subrama-
nian et al., 2005).
qRT-PCR
Total RNAwas extracted with RNeasy Micro Kit (QIAGEN), treated
with DNase I Kit (QIAGEN), and reverse transcribed using Super-
Script III Kit (Invitrogen) as per the manufacturer’s instructions.
miRNA qRT-PCR has been described previously (Moltzahn
et al., 2011). Primers and probes can be found in Supplemental
Information.7 hESC eBCs. Doxycycline treatment as in (B). n = 6 independent
erage ± SEM. Statistical significance was calculated using unpaired
ificant.
BCs. Doxycycline treatment, number of replicates and statistics as in
ependent samples for Dox–, n = 10 independent samples for Dox+.
ng unpaired two-tailed t test. n.s., not significant. Compare with
. Dox treatment, number of replicates, and statistics as in (C).
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Western Blots
Antibodies and concentrations used can be found in Supplemental
Information. Imaging was performed using an Odyssey LICOR
scanner and quantified using ImageJ.T7 Endonuclease I Assay
Genomic regions flanking the CRSIPR target sites were PCR ampli-
fied. Purified PCR products were denatured and reannealed and
then treated with the T7 Endonuclease I Assay (New England Bio-
labs). Indel percentage was determined by the formula: %gene
modification = 100 3 (1–(1–fraction cleaved)1/2).GSIS Assays
For static insulin secretion assays, cells were treated at the indi-
cated glucose concentrations, and supernatant was collected.
For dynamic insulin secretion assays, eBCs were assayed using
the perifusion system from Biorep Technologies. Flow-through
was collected over the course of the experiment. C-peptide levels
were measured using the STELLUX Chemi Human C-peptide
ELISA kit (Alpco).ACCESSION NUMBERS
The GEO accession number for the genomic data presented is
GSE108654.SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2019.11.009.
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